HomeCompareEARS vs EPRT

EARS vs EPRT: Dividend Comparison 2026

EARS yields 65.68% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EARS wins by $794.1K in total portfolio value
10 years
EARS
EARS
● Live price
65.68%
Share price
$3.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$857.5K
Annual income
$214,640.91
Full EARS calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — EARS vs EPRT

📍 EARS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEARSEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EARS + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EARS pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EARS
Annual income on $10K today (after 15% tax)
$5,582.92/yr
After 10yr DRIP, annual income (after tax)
$182,444.77/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EARS beats the other by $171,530.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EARS + EPRT for your $10,000?

EARS: 50%EPRT: 50%
100% EPRT50/50100% EARS
Portfolio after 10yr
$460.4K
Annual income
$113,740.81/yr
Blended yield
24.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

EARS
No analyst data
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EARS buys
0
EPRT buys
0
No recent congressional trades found for EARS or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEARSEPRT
Forward yield65.68%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$857.5K$63.4K
Annual income after 10y$214,640.91$12,840.73
Total dividends collected$722.8K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EARS vs EPRT ($10,000, DRIP)

YearEARS PortfolioEARS Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$17,268$6,568.14$11,205$505.18+$6.1KEARS
2$29,077$10,599.97$12,672$682.46+$16.4KEARS
3$47,793$16,681.04$14,490$930.48+$33.3KEARS
4$76,764$25,624.68$16,786$1,282.69+$60.0KEARS
5$120,602$38,464.70$19,753$1,791.56+$100.8KEARS
6$185,521$56,477.71$23,677$2,541.64+$161.8KEARS
7$279,704$81,195.93$29,008$3,672.99+$250.7KEARS
8$413,691$114,407.58$36,463$5,425.08+$377.2KEARS
9$600,792$158,142.40$47,238$8,221.57+$553.6KEARS
10$857,488$214,640.91$63,385$12,840.73+$794.1KEARS

EARS vs EPRT: Complete Analysis 2026

EARSStock

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Full EARS Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this EARS vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EARS vs SCHDEARS vs JEPIEARS vs OEARS vs KOEARS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.